Published: 24 July 2018
Author(s): Maxime Samson, Hervé Devilliers, Kim Heang Ly, François Maurier, Boris Bienvenu, Benjamin Terrier, Pierre Charles, Loïc Guillevin, Jean-François Besancenot, Eric Liozon, Anne Laure Fauchais, Romaric Loffroy, Christine Binquet, Sylvain Audia, Raphaèle Seror, Xavier Mariette, Bernard Bonnotte
Section: Original Article
The aim of this study was to evaluate tocilizumab (TCZ) as an add-on therapy to glucocorticoids (GC) during the first 3 months of treatment of giant cell arteritis (GCA).
